EGFR and neoplasm: Having potent anti-tumor activity in laboratory settings, even at doses where other EGFR antibodies were found to be much less effective, zalutumumab was recognized as having the properties required for treatment of a variety of cancers, and was awarded fast track status from the U.S. FDA for head and neck cancer patients who have failed standard therapies (Table 3).